BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer

Modern Pathology

Volumn 27, Issue 5, 2014, Pages 644-650

  Toon, Christopher W ^a,b,c   Chou, Angela ^d   Desilva, Keshani ^e   Chan, Joseph ^a,c   Patterson, Jillian ^a   Clarkson, Adele ^a,e   Sioson, Loretta ^a,e   Jankova, Lucy ^a,c   Gill, Anthony J ^a,c,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Histopath Pathology   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

BRAFV600E; colorectal carcinoma; microsatellite instability; mismatch repair deficiency

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TUMOR MARKER; B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; FEMALE; FOLLOW UP; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OVERALL SURVIVAL; PRIORITY JOURNAL; VALIDATION STUDY; WILD TYPE; CARCINOMA; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COLORECTAL TUMOR; GENETICS; METABOLISM; MICROSATELLITE INSTABILITY; MIDDLE AGED; MORTALITY; MUTATION; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SURVIVAL RATE; YOUNG ADULT;

EID: 84899894977     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.200     Document Type: Article

References (30)

1. Ludwig JA, Weinstein JN. Biomarkers in cancerstaging, prognosis and treatment selection. Nat RevCancer 2005;5:845-856.
2. Toon CW, Walsh MD, Chou A, et al. BRAFV600EImmunohistochemistry facilitates universal screeningof colorectal cancers for Lynch syndrome. Am J SurgPathol 2013;37:1592-1602.
3. Ogino S, Nosho K, Kirkner GJ, et al. CpG islandmethylator phenotype, microsatellite instability, BRAFmutation and clinical outcome in colon cancer. Gut2009;58:90-96.
4. Pai RK, Jayachandran P, Koong AC, et al. BRAFmutated,microsatellite- stable adenocarcinoma of theproximal colon: an aggressive adenocarcinoma withpoor survival, mucinous differentiation, and adversemorphologic features. Am J Surg Pathol 2012;36:744-752.
5. NCCNClinical practice guidelines in oncology.Colon Cancer. Version 3. 2013. Available at http://www.nccn.org/professionals/physician-gls/pdf/colon. pdf. Accessed: 1 August 2013.
6. Di Nicolantonio F, Martini M, Molinari F, et al. WildtypeBRAF is required for response to panitumumab orcetuximab in metastatic colorectal cancer. J Clin Oncol2008;26:5705-5712.
7. Prahallad A, Sun C, Huang S, et al. Unresponsivenessof colon cancer to BRAF(V600E) inhibition throughfeedback activation of EGFR. Nature 2012;483:100-103.
8. Capper D, Voigt A, Bozukova G, et al. BRAF V600Especificimmunohistochemistry for the exclusion ofLynch syndrome in MSI-H colorectal cancer. Int JCancer 2013;133:1624-1630.
9. Sinicrope FA, Smyrk TC, Tougeron D, et al. Mutationspecificantibody detects mutant BRAF(V600E) proteinexpression in human colon carcinomas. Cancer2013;119:2765-2770.
10. Thiel A, Heinonen M, Kantonen J, et al. BRAFmutation in sporadic colorectal cancer and Lynchsyndrome. Virchow's Arch; (Epub ahead of Print) 2013.
11. Popat S, Hubner R, Houlston RS. Systematic review ofmicrosatellite instability and colorectal cancer prognosis.J Clin Oncol 2005;23:609-618.
12. Kim GP, Colangelo LH, Wieand HS, et al. Prognosticand predictive roles of high-degree microsatelliteinstability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and BowelProject Collaborative Study. J Clin Oncol 2007;25:767-772.
13. Sargent DJ, Marsoni S, Monges G, et al. Defectivemismatch repair as a predictive marker for lack ofefficacy of fluorouracil based adjuvant therapy incolon cancer. J Clin Oncol 2010;28:3219-3226.
14. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNAmismatch repair status and colon cancer recurrenceand survival in clinical trials of 5-fluorouracil-basedadjuvant therapy. J Natl Cancer Inst 2011;103:863-875.
15. Bertagnolli MM, Redston M, Compton CC, et al.Microsatellite instability and loss of heterozygosity atchromosomal location 18q: prospective evaluation ofbiomarkers for stages II and III colon cancer-a studyof CALGB 9581 and 89803. J Clin Oncol 2011;29:3153-3162.
16. Roth AD, Delorenzi M, Tejpar S, et al. Integratedanalysis of molecular and clinical prognostic factors instage II/III colon cancer. J Natl Cancer Inst 2012;104:1635-1646.
17. Hutchins G, Southward K, Handley K, et al. Value ofmismatch repair, KRAS, and BRAF mutations inpredicting recurrence and benefits from chemotherapyin colorectal cancer. J Clin Oncol 2011;29:1261-1270.
18. Eklö f V, Wikberg ML, Edin S, et al. The prognostic roleof KRAS, BRAF, PIK3CA and PTEN in colorectalcancer. Br J Cancer 2013;108:2153-2163.
19. Richman SD, Seymour MT, Chambers P, et al. KRASand BRAF mutations in advanced colorectal cancer areassociated with poor prognosis but do not precludebenefit from oxaliplatin or irinotecan: results from theMRC FOCUS trial. J Clin Oncol 2009;27:5931-5937.
20. Phipps AI, Buchanan DD, Makar KW, et al. BRAFmutation status and survival after colorectal cancerdiagnosis according to patient and tumor characteristics.Cancer Epidemiol Biomarkers Prev 2012;21: 1792-1798.
21. Ogino S, Shima K, Meyerhardt JA, et al. Predictive andprognostic roles of BRAF mutation in stage III coloncancer: results from intergroup trial CALGB 89803.Clin Cancer Res 2012;18:890-900.
22. Yokota T, Ura T, Shibata N, et al. BRAF mutation is apowerful prognostic factor in advanced and recurrentcolorectal cancer. Br J Cancer 2011;104:856-862.
23. Farina-Sarasqueta A, van Lijnschoten G, Moerland E,et al. The BRAF V600E mutation is an independentprognostic factor for survival in stage II and stage IIIcolon cancer patients. Ann Oncol 2010;21:2396-2402.
24. Kalady MF, Dejulius KL, Sanchez JA, et al. BRAFmutations in colorectal cancer are associated withdistinct clinical characteristics and worse prognosis.Dis Colon Rectum 2012;55:128-133.
25. Barault L, Charon-Barra C, Jooste V, et al. Hypermethylatorphenotype in sporadic colon cancer: study on apopulation-based series of 582 cases. Cancer Res2008;68:8541-8546.
26. French AJ, Sargent DJ, Burgart LJ, et al. Prognosticsignificance of defective mismatch repair and BRAFV600E in patients with colon cancer. Clin Cancer Res2008;14:3408-3415.
27. Zlobec I, Kovac M, Erzberger P, et al. Combinedanalysis of specific KRAS mutation, BRAF and microsatelliteinstability identifies prognostic subgroups ofsporadic and hereditary colorectal cancer. Int J Cancer2010;127:2569-2575.
28. Samowitz WS, Sweeney C, Herrick J, et al. Poorsurvival associated with the BRAF V600E mutationin microsatellite-stable colon cancers. Cancer Res2005;65:6063-6069.
29. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatelliteinstability and BRAF mutation testing in colorectalcancer prognostication. J Natl Cancer Inst2013;105:1151-1156.
30. Adackapara CA, Sholl LM, Barletta JA, et al. Immunohistochemistryusing the BRAF V600E mutationspecificmonoclonal antibody VE1 is not a usefulsurrogate for genotyping in colorectal adenocarcinoma.Histopathology 2013;63:187-193.